Xcout IntelBriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
Subscribe to see BriaCell Therapeutics Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
BriaCell Therapeutics Corp. at a glance
BriaCell Therapeutics Corp. is a biotech company headquartered in West Vancouver, Canada. It is publicly listed (BCTX) with a market capitalisation of $6.7M. Xcout tracks 13 named people at BriaCell Therapeutics Corp., including William V. Williams (Chief Executive Officer, President & Director).
BriaCell Therapeutics Corp. leadership
- William V. WilliamsChief Executive Officer, President & Director
- Gadi LevinChief Financial Officer & Corporate Secretary
- Giuseppe Del PrioreChief Medical Officer
- Miguel A. Lopez-LagoChief Scientific Officer
- Jamieson BondarenkoChairman of the Board
- Charles Louis Wiseman FACPFounder, Principal Research Advisor & Member of Scientific Advisory Board
7 more named people on record for BriaCell Therapeutics Corp., with roles, board committees and tenure — see the full roster →
Investors
BriaCell Therapeutics Corp. competitors
A few of BriaCell Therapeutics Corp.'s closest competitors — see the full list of competitors and alternatives →
ImStar Therapeutics Inc. is a biotechnology company headquartered in Vancouver, British Columbia, focused on breakthrough science and drug discovery.
Reverb Therapeutics is a biotechnology research company headquartered in Vancouver, British Columbia. The company focuses on cancer therapeutics by developing its proprietary Amplify-R platform designed to intelligently adjust and tune the body's natural immune system.
BriSTAR Immunotech Limited is a clinical-stage cell therapy company actively developing universal cell therapies with a differentiated product pipeline and offices in Beijing and Suzhou.
Imvax, Inc. is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, focused on developing personalized, whole-cell immunotherapies for the treatment of various cancers.
Arcellx, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, dedicated to developing innovative immunotherapies and cell therapies for cancer patients.
BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.
Get BriaCell Therapeutics Corp.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on BriaCell Therapeutics Corp. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access